A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on ...

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts ...

It wasn't that long ago that Madrigal Pharmaceuticals was in a similar situation. A pre-commercial biotech with a promising ...

For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Alumis: Top-line ...

Learn more about whether Legend Biotech Corporation or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Nanobiotix is a small French biotechnology company. It has secured financing from Johnson & Johnson and elsewhere. It's not a no-brainer investment, but it might do well. Nanobiotix (NASDAQ: NBTX) is ...